The future emerges

Emergent BioSolutions Inc. has sustained itself for years with a steady stream of government grants and contracts for infectious disease and biodefense products, but has been looking for acquisitions that could diversify its revenue stream into products with more growth potential.

The company says its proposed acquisition of autoimmune and cancer company Trubion Pharmaceuticals Inc. provides the diversification it has been seeking and leverages its biologics manufacturing expertise...